AgeX Therapeutics, a subsidiary of BioTime based in Alameda, Calif., focuses on developing therapeutics that target fundamental mechanisms of human aging, including telomerase-mediated cell immortality and regenerative biology. Its pipeline includes preclinical cell-based therapies AGEX-BAT1 and AGEX-VASC1, the drug candidate AGEX-iTR1547 derived from its induced Tissue Regeneration (iTR) technology, and Renelon™, a first-generation iTR product planned for topical development via a 510(k) pathway. The company also markets genomic interpretation algorithms through its LifeMap subsidiary and PSC-derived heart muscle cells for drug screening through its ESI BIO division. AgeX plans to continue advancing its preclinical programs and pursue commercial development paths for its iTR products. Financially, AgeX recently closed a $5.0 million equity financing and reports additional recent financing sources that management says provide sufficient capital into 2020. AgeX Therapeutics is a biotechnology subsidiary of BioTime focused on applying cell immortality and regenerative biology to treat aging and age‑related diseases. Formed in early 2017 and based in Alameda, Calif., AgeX's initial product programs include pluripotent stem cell‑derived brown adipocytes (AGEX‑BAT1), vascular progenitors (AGEX‑VASC1), and induced Tissue Regeneration (iTR). Planned indications for those programs are type II diabetes, cardiac ischemia, and cancer. The company raised $10 million in equity financing to fund preclinical development and to build its operational infrastructure, and BioTime remains the majority owner with about 87% of AgeX's outstanding shares. BioTime has licensed or assigned certain assets to AgeX and assigned ownership of private subsidiaries LifeMap Sciences, Ascendance Biotechnology, and ReCyte Therapeutics to AgeX while retaining core ophthalmology, orthopedics, medical aesthetics, and drug delivery assets. Management includes Michael D. West, Ph.D., who will serve as AgeX's CEO; the company may register and distribute a portion of its shares to BioTime shareholders, potentially enabling AgeX to trade publicly.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2018